...
首页> 外文期刊>Journal of Medicine, Physiology and Biophysics >Association of Mean Serum Vitamin B-12 levels in Patients with Type II Diabetes Mellitus patients with and without Metformin therapy.
【24h】

Association of Mean Serum Vitamin B-12 levels in Patients with Type II Diabetes Mellitus patients with and without Metformin therapy.

机译:II型糖尿病患者患者的平均血清维生素B-12水平的关联患者患者患者患者患者,无需二甲双胍治疗。

获取原文

摘要

Objective: To determine mean serum vitamin B12 levels in patients with type II diabetes mellitus using metformin. Study Design: Prospective Cross sectional Study Location and Duration: Department of Medicine, Nishtar Hospital Multan, from March 2018 to September 2019. Methodology: Ninety two patients were involved after getting informed consent. HbA1 c, body mass index and blood pressure and deficiency for vitamin B12 was assessed by using electro-chem-iluminescence immunoassay method. B12 levels were categorized as normal (220pg/ml), possibly deficient (150 to 220 pg/ml) and definitely deficient (150pg/ml). Neuropathy was assessed and was classified by using Toronto clinical scoring system by the researcher himself. All the data was subjected to statistical analysis using computer software SPSS version 23. Continuous variables were analyzed by their mean and standard deviation while quantitative variables were analyzed by frequency and percentages. Chi square test was applied and P value less than or equal to 0.05 was taken as significant. Results: Mean Serum B-12 levels were 378.42±161.27 pg/ml and 488.90±147.02 pg/ml in metformin and non-metformin groups, respectively. The difference was statistically significant (p=0.001). The patients who were possibly deficient and definitely deficient were 15 (28.30%) and 5 (9.43%) in metformin group and were significantly more (p=0.006) than non-metformin group i.e. 4 (10.26%) and 0. The mean Toronto Neuropathy Score was statistically different (p0.001) between metformin group (6.03±1.73) and non-metformin group (4.13±1.75). The patients who had mild neuropathy and moderate neuropathy were 23 (43.39%) and 5 (9.43%) in metformin group, while 6 (15.38%) and 2 (5.13%) in non-metformin group. Statistically, both the groups were significantly different (p=0.005). Conclusion: At the end of this study conclusion can be made that metformin use for type II diabetes mellitus is strongly associated with vitamin B12 deficiency and worsening of already susceptible neuropathy.
机译:目的:使用二甲双胍确定II型糖尿病患者的平均血清维生素B12水平。研究设计:前瞻性横截面研究位置和持续时间:医学系,Nishtar Hospital Multan,2018年3月至2019年9月。方法:在获得知情同意后涉及九十二名患者。通过使用电气化学 - 髂管免疫测定法评估HBA1c,体重指数和血压和维生素B12的缺乏。 B12水平分类为正常(> 220pg / ml),可能缺乏(150至220pg / ml),绝对缺乏(<150pg / ml)。评估神经病,并通过研究人员自己使用多伦多临床评分系统进行分类。所有数据都使用计算机软件SPSS版本23进行统计分析。通过其平均值和标准偏差分析连续变量,同时通过频率和百分比分析定量变量。施用Chi正方形试验,并将P值小于或等于0.05。结果:平均血清B-12水平分别为378.42±161.27pg / ml,分别为二甲双胍和非二甲双胍组的488.90±147.02 pg / ml。差异有统计学意义(p = 0.001)。可能缺乏且肯定缺乏的患者在二甲双胍组中为15(28.30%)和5(9.43%),比非二甲双胍组均显着(p = 0.006),即4(10.26%)和0.平均多伦多在二甲双胍组(6.03±1.73)和非二甲双胍组(4.13±1.75)之间,神经病变评分在统计学上有所不同(P <0.001)(4.1​​3±1.75)。具有轻度神经病变和中度神经病变的患者在二甲双胍组中为23(43.39%)和5(9.43%),而非二甲双胍组6(15.38%)和2(5.13%)。统计上,两组均显着不同(P = 0.005)。结论:在本研究结束时,结论可以使二甲双胍用于II型糖尿病的用途与维生素B12缺乏强烈有关,并且对已经易感神经病变恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号